You are here: Industry Insights > Novo Nordisk

News List

Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy prnasia
November 06, 2020
Results of a phase 3a trial showed that investigational drug semaglutide 2.4 mg once-weekly subcutaneous as an adjunct to intensive behavioural therapy (IBT) demonstrated significantly more body weight loss compared to placebo plus IBT.
NICE recommends Liraglutide for treatment of obesity and non-diabetic hyperglycaemia europeanpharmaceuticalreview
November 06, 2020
Liraglutide (Saxenda) will be offered to adults with non-diabetic hyperglycaemia and a high risk of cardiovascular disease.
Novo Nordisk’s Saxenda bags NICE recommendation pharmatimes
November 05, 2020
Novo Nordisk’s obesity management treatment Saxenda (liraglutide) has been recommended for use by the UK’s National Institute for Health and Care Excellence (NICE).
NICE recommends Novo Nordisk treatment for adults with obesity pharmaceutical-technology
November 02, 2020
National Institute for Health and Care Excellence (NICE) has recommended a new treatment option developed by Novo Nordisk for adults with obesity and non-diabetic hyperglycaemia.
UK launch for Novo's new diabetes pill pharmatimes
September 02, 2020
Novo Nordisk has launched in the UK the first 'protein in a pill' treatment for type II diabetes.
Evotec and Novo Nordisk Form Strategic Alliance contractpharma
August 19, 2020
Evotec SE and Novo Nordisk have announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease.
Novo Nordisk resumes late-stage haemophilia trials pharmatimes
August 17, 2020
Novo Nordisk is set to resume the phase 3 clinical trials of concizumab in haemophilia A and B, with or without inhibitors, following a previous safety scare.
Novo Nordisk's AM833 shows early success in obesity trials pharmatimes
June 22, 2020
Novo Nordisk has unveiled headline results from two clinical trials with a novel once-weekly subcutaneous amylin analogue (AM833) - a Phase II monotherapy trial and a Phase I combination trial of AM833 and once-weekly subcutaneous semaglutide.
Novo snaps up cardio-renal group Corvidia pharmatimes
June 16, 2020
Novo Nordisk has signed a deal to acquire Corvidia Therapeutics, a privately held, clinical stage company with a focus on the research and development of transformative therapies for cardio-renal diseases.
Novo Nordisk to acquire Corvidia Therapeutics for $725m pharmaceutical-technology
June 15, 2020
Danish healthcare company Novo Nordisk has signed a definitive agreement to acquire US-based Corvidia Therapeutics, which develops and commercialises therapies for cardio-renal diseases, for an upfront payment of $725m.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 13 14 Next page